Revisiting Non-Cancer Drugs for Cancer Therapy

Author(s): Eun Ju Yang, Changjie Wu, Yifan Liu, Junfang Lv, Joong Sup Shim

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 19 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Although tremendous effort has been made over the past century to treat cancer effectively, the pace of drug development is far behind the increasing rate of cancer incidence and mortality. There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the quality of life of patients and complicated drug development processes that are costly and time consuming. Drug repositioning has recently gained increasing attention among cancer researchers as this approach utilizes existing drugs and is significantly cost- and time-effective. Existing drugs, particularly non-cancer drugs, have favorable safety profiles in humans and serve as an ever-increasing source for new anticancer drug discovery. Here we review the recent examples of drug repositioning of existing non-cancer drugs for preclinical and clinical introductions of cancer therapy.

Keywords: Cancer, Disulfiram, Doxycycline, Drug repositioning, Existing drugs, Mebendazole, Pyrvinium pamoate, Triclosan.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [2144 - 2155]
Pages: 12
DOI: 10.2174/1568026616666160216154441
Price: $65

Article Metrics

PDF: 67
PRC: 1